India Pharmaceutical Cdmo Market Size & Outlook, 2025-2033

The pharmaceutical cdmo market in India is expected to reach a projected revenue of US$ 27,923.1 million by 2033. A compound annual growth rate of 8.5% is expected of India pharmaceutical cdmo market from 2025 to 2033.
Revenue, 2024 (US$M)
$13,498.1
Forecast, 2033 (US$M)
$27,923.1
CAGR, 2025 - 2033
8.5%
Report Coverage
India

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

India pharmaceutical cdmo market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

India pharmaceutical cdmo market highlights

  • The India pharmaceutical cdmo market generated a revenue of USD 13,498.1 million in 2024 and is expected to reach USD 27,923.1 million by 2033.
  • The India market is expected to grow at a CAGR of 8.4% from 2025 to 2033.
  • In terms of segment, api was the largest revenue generating product in 2024.
  • API is the most lucrative product segment registering the fastest growth during the forecast period.


Pharmaceutical cdmo market data book summary

Market revenue in 2024USD 13,498.1 million
Market revenue in 2033USD 27,923.1 million
Growth rate8.4% (CAGR from 2025 to 2033)
Largest segmentApi
Fastest growing segmentAPI
Historical data2021 - 2023
Base year2024
Forecast period2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationAPI, Drug Product
Key market players worldwideLonza Group Ltd, Thermo Fisher Scientific Inc, Labcorp Holdings Inc, Catalent Inc, Wuxi AppTec Co Ltd, Siegfried Holding AG, Nipro Corp, Piramal Pharma Solutions, Recipharm Venture Fund, CordenPharma, Cambrex, Bushu Pharmaceuticals, Seqens


Other key industry trends

  • In terms of revenue, India accounted for 8.7% of the global pharmaceutical cdmo market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, China pharmaceutical cdmo market is projected to lead the regional market in terms of revenue in 2033.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 39,514.1 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Pharmaceutical CDMO Market Companies

Name Profile # Employees HQ Website
Seqens View profile 1001-5000 Écully, Rhone-Alpes, France, Europe https://www.seqens.com/en
Bushu Pharmaceuticals View profile - Saitama, Saitama, Japan, Asia http://bushu-seiyaku.co.jp/en/
Recipharm Venture Fund View profile - Stockholm, Stockholms Lan, Sweden, Europe -
Cambrex View profile 1001-5000 East Rutherford, New Jersey, United States, North America http://www.cambrex.com
CordenPharma View profile 5001-10000 Plankstadt, Baden-Wurttemberg, Germany, Europe http://cordenpharma.com
Piramal Pharma Solutions View profile 1001-5000 Riverview, Michigan, United States, North America http://www.piramalpharmasolutions.com/
Siegfried Holding AG View profile 4180 Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 https://www.siegfried.ch
Catalent Inc View profile 17219 14 Schoolhouse Road, Somerset, NJ, United States, 08873 https://www.catalent.com
Wuxi AppTec Co Ltd View profile 41116 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 https://www.wuxiapptec.com
Nipro Corp View profile 39713 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 http://www.nipro.co.jp
Labcorp Holdings Inc View profile 67000 358 South Main Street, Burlington, NC, United States, 27215 https://www.labcorp.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
Lonza Group Ltd View profile 18000 Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 https://www.lonza.com

India pharmaceutical cdmo market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical cdmo market will help companies and investors design strategic landscapes.


Api was the largest segment with a revenue share of 81.7% in 2024. Horizon Databook has segmented the India pharmaceutical cdmo market based on api, drug product covering the revenue growth of each sub-segment from 2021 to 2033.


India is emerging as one of the lucrative markets for pharmaceutical contract development and manufacturing across the globe. This can be attributed to low costs, the availability of industry experts, and the presence of WHO-cGMP-compliant facilities. 

Furthermore, some of the key players in India’s pharmaceutical contract development and manufacturing services are Wuxi AppTec; Charles River Laboratories International, Inc.; IQVIA; Recipharm AB; and Catalent, Inc.Several CMOs & CROs operating in India have expanded their facilities to meet the growing demand for pharmaceuticals.

Reasons to subscribe to India pharmaceutical cdmo market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of India pharmaceutical cdmo market databook

  • Our clientele includes a mix of pharmaceutical cdmo market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the India pharmaceutical cdmo market , including forecasts for subscribers. This country databook contains high-level insights into India pharmaceutical cdmo market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

India Product - Pharmaceutical Cdmo Market size, 2024 - 2033 (US$M)

India Pharmaceutical CDMO Market Outlook Share, 2024 & 2033 (US$M)

India Product - Pharmaceutical Cdmo Market size, 2024 - 2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online